Results 151 to 160 of about 25,663 (196)
Carbapenem-resistant Gram-negative pathogens: molecular epidemiology, diagnostic advances, and emerging therapeutic strategies. [PDF]
Front MicrobiolKhan M, Patil P, Rathored J.
europepmc +1 more source
A multicenter performance evaluation of aztreonam-avibactam gradient diffusion susceptibility testing for <i>Enterobacterales</i>. [PDF]
J Clin MicrobiolBui TI +7 more
europepmc +1 more source
Co-Administration Dosing of Ceftazidime-Avibactam and Aztreonam in Patients with Varying Renal Function for Carbapenem-Resistant Enterobacterales Infections via Monte Carlo Simulation. [PDF]
Infect ChemotherHemapanpairoa J +3 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Infection Control & Hospital Epidemiology, 1990
Aztreonam, the first licensed monobactam in the United States, is a β-lactam antimicrobial agent with a unique structure and in vitro spectrum of activity. The drug is active only against gram-negative aerobic bacteria in vitro, thus resembling the spectrum of aminoglycosides, but displays the safety profile typical of β-lactam agents.
A R, Tunkel, W M, Scheld
+6 more sources
Aztreonam, the first licensed monobactam in the United States, is a β-lactam antimicrobial agent with a unique structure and in vitro spectrum of activity. The drug is active only against gram-negative aerobic bacteria in vitro, thus resembling the spectrum of aminoglycosides, but displays the safety profile typical of β-lactam agents.
A R, Tunkel, W M, Scheld
+6 more sources
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1986
Aztreonam is a new, totally synthetic beta‐lactamase agent — the first monobactam. It is highly resistant to hydrolytic inactivation caused by plasmid‐mediated (except PSE‐2 enzyme found in some Pseudomonas species) or chromosomally mediated beta‐lactamases (except for K1 produced by rare strains of Klebsiella oxytoca).
S J, Childs, G P, Bodey
openaire +3 more sources
Aztreonam is a new, totally synthetic beta‐lactamase agent — the first monobactam. It is highly resistant to hydrolytic inactivation caused by plasmid‐mediated (except PSE‐2 enzyme found in some Pseudomonas species) or chromosomally mediated beta‐lactamases (except for K1 produced by rare strains of Klebsiella oxytoca).
S J, Childs, G P, Bodey
openaire +3 more sources
Nature Reviews Drug Discovery, 2010
In February 2010, aztreonam for inhalation solution (Cayston; Gilead) - an inhalable formulation of the monobactam antibiotic aztreonam and lysine - was approved by the US FDA to improve respiratory symptoms in patients with cystic fibrosis infected with Pseudomonas aeruginosa.
O'Sullivan, Brian P. +2 more
openaire +3 more sources
In February 2010, aztreonam for inhalation solution (Cayston; Gilead) - an inhalable formulation of the monobactam antibiotic aztreonam and lysine - was approved by the US FDA to improve respiratory symptoms in patients with cystic fibrosis infected with Pseudomonas aeruginosa.
O'Sullivan, Brian P. +2 more
openaire +3 more sources
Obstetrics and Gynecology Clinics of North America, 1992
Aztreonam is a synthetic monobactam antibiotic that has excellent activity against aerobic gram-negative bacilli. It can be used as a single agent for the treatment of upper urinary tract infections caused by organisms resistant to the cephalosporins and ampicillin.
openaire +3 more sources
Aztreonam is a synthetic monobactam antibiotic that has excellent activity against aerobic gram-negative bacilli. It can be used as a single agent for the treatment of upper urinary tract infections caused by organisms resistant to the cephalosporins and ampicillin.
openaire +3 more sources
ACS Medicinal Chemistry Letters, 2020 Aztreonam, first discovered in 1980, is an FDA approved, intravenous, monocyclic beta-lactam antibiotic. Aztreonam is active against Gram-negative bacteria and is still used today. The oral bioavailability of aztreonam in humans is less than 1%.
Matthew Duncton, Eric Gordon
exaly +2 more sources